Top

Tijdschrift voor Gerontologie en Geriatrie

Gepubliceerd in:

01-10-2011

Leverlijden bij oudere personen

Auteurs: dr. T. Ghillemijn, W. Laleman, J. Flamaing

Gepubliceerd in: Tijdschrift voor Gerontologie en Geriatrie | Uitgave 5/2011

Samenvatting

Een niet te verwaarlozen percentage van de morbiditeit en de mortaliteit bij oudere personen is toe te schrijven aan leverlijden.

Een bespreking van de klinische presentatie en de vooropgestelde behandeling van geselecteerde leverziekten bij oudere personen is daarom op zijn plaats.

Aan de hand van literatuurgegevens wordt ingegaan op het klinisch verloop en de behandelingsmodaliteiten van virale en auto-immune hepatitis, hepatocellulair carcinoma en toxisch leverlijden bij oudere personen.

vorige artikel Een handreiking voor familieleden over palliatieve zorg bij dementie: evaluatie door zorgverleners en familieleden

volgende artikel Recente onderzoeksliteratuur

Lamberts S, van den Beld A, van der Lely A-J. The endocrinology of aging. Science 1997; 278: 419–424.PubMedCrossRef

Popper H. Aging and the liver. In: Popper H, Schaffner F, et al. Progress in liver disease, volume VIII, 1986: 659–83.

Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. Journal of hepatology 2001; 35: 297–306.PubMedCrossRef

Takubo K, Nakamuro K, Izumiyama N, et al. Telomere shortening with age in human liver. J Gerontol A Biol Sci Med Sci 2000; 55: 533–536.CrossRef

Wynne H, Cope L, Mutch E, et al. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 1989; 9: 297–301.PubMedCrossRef

Le Couteur DG, Fraser R, Cogger V, McLean A. Hepatic pseudocapillarisation and atherosclerosis in ageing. The Lancet 2002; 359: 1612–1615.CrossRef

Regev A, Schiff E. Liver disease in the elderly. Gastroenterology Clinics of NorthAmerica 2001; 30: 547–563.CrossRef

Junaidi O, Di Bisceglie A. Aging liver and hepatitis. Clin Geriatr Med 2007; 23: 889–903.PubMedCrossRef

Genton A,D’Acremont V, Furrer HJ, Hatz C, Loutan L. Hepatitis A vaccines and the elderly. Travel Medicine and Infectious Disease 2006; 4: 303–312.PubMedCrossRef

10.

D’Acremont V, Herzog C, Genton B. Immunogenicity and safety of a virosomal hepatitis. A vaccine (Epaxal) in the elderly. J Travel Med 2006; 13: 78–83PubMedCrossRef

11.

Costas L, Vilella A, Trilla A, et al. Vaccination Strategies against Hepatitis A in travelers older than 40 years: an economic evaluation. Journal of Travel Medicine 2009; 6: 344–348.CrossRef

12.

Kondo Y, Tsukada K, Takeuchi T, et al. High carrier rate after hepatitis B virus infection in the elderly. Hepatology 1993; 18: 768–74.PubMedCrossRef

13.

EASL Clinical Practice Guidelines: Management of chronic hepatitis B. Journal of Hepatology 2009; 50: 227–242.

14.

Franchis R, Hadengue A, Lau GK, et al. EASL international consensus conference on Hepatitis B. J Hepatology 2003; 39: S3–25.

15.

Lok AS, McMahon BJ. Chronic hepatitis B. Update of recommendations. Hepatology 2004; 39: 857–61.PubMedCrossRef

16.

Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825–32.PubMedCrossRef

17.

Roudot-Thoraval F, Bastie A, Pawlotsky JM, et al. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6664 patients. Hepatology 1997; 26: 485–90.PubMedCrossRef

18.

Floreani A, Bertin T, Soffiati G, et al. Antihepatitis C virus in the elderly: a seroepidemiological study in a home for the aged. Gerontology 1992; 38: 214–6.PubMedCrossRef

19.

TorresMand Poynard T. Risk factors for liver fibrosis progression in patients with chronic hepatitis C. Annals of Hepatology 2003; 2: 5–11.PubMed

20.

Strader DB,Wright T, Thomas DL, et al. Diagnosis, management , and treatment of hepatitis C. Hepatology 2004; 39:1147–71.PubMedCrossRef

21.

MannsMP, McHutchison JG, Gordon SC, et al. Peginterferon a-2b plus ribavirin compared with interferon a-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958–65.PubMedCrossRef

22.

FriedMW, ShiffmanML, Reddy KR, et al. Peginterferon a-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–82.PubMedCrossRef

23.

Bresci G, Del Corso L, Romanelli Am, et al. The use of recombinant interferon alfa-2b in elderly patients with anti-HCV-positive chronic active hepatitis. JAm Geriatr Soc, 1993; 41, 857.

24.

Van Thiel et al. Treatment of hepatitis C virus in the elderly persons with interferon a. J gerontology, 1995; 6: 330–333.

25.

Horiike N, Masumoto T, Nakanishi K, et al. Interferon therapy for patients more than 60 years of age with chronic hepatitis C. J Gastroenterol Hepatol 1995; 10: 246–9.PubMedCrossRef

26.

Imai Y, Kasahara A, Tanaka H, et al. Interferon therapy for aged patients with chronic hepatitis C. J Gastroenterol, 2004; 39: 1069–77.PubMedCrossRef

27.

Shiratori Y, Ito Y, Yokosuka O, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med, 2005; 142: 105–14.PubMed

28.

Thabut D, Le Calvez S, Thibault V, et al. Hepatitis C in patients 65 years or older: a severe and neglected curable disease?. AmJ Gastroenterol 2006; 101: 1260–7.CrossRef

29.

Nudo CG,Wong P, Hilzenrat N, et al. Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. Can J Gastroenterol 2006; 20: 589–92.PubMed

30.

Mindikoglu A, Miller R. Hepatitis C in the Elderly: Epidiomology, Natural History, and Treatment. Clinical gastroenterology and hepatoloy 2009; 7: 128–134.CrossRef

31.

Honda T, Katano Y, Shimizu J, et al. Efficacy of peginterferon-alfa-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C. Liver International 2009.

32.

Ikeda K, Arase Y, Kawamura Y, et al. Necessities of Interferon therapy in Elderly patients with Chronic Hepatitis C. The American Journal of Medicine 2009; 122: 479–486.PubMedCrossRef

33.

Floreani A, Minola E, Carderi I, et al. Are elderly patients poor candidates for pegylated interferon plus ribavirin in the treatment of chronic hepatitis C? J. Am. Geriatr. Soc 2006; 54: 549–550.CrossRef

34.

Al-Chalabi T, Boccato S, Portmann B, McFarlane I, Heneghan M. Autoimmune hepatitis in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. Journal of Hepatology, 2006; 45: 575–583.PubMedCrossRef

35.

Verslype C, George C, Buchel E, Nevens F, Van SteenbergenW, Fevery J. Diagnosis and treatment of autoimmune hepatitis at age 65 and older. Aliment Pharmacol Ther, 2005; 21: 695–699.PubMedCrossRef

36.

Collier D, Curless R, Bassendine M, James O. Clinical features and prognosis of hepatocellulair carcinoma in Britain in relation to age. Age and ageing, 1994; 23: 22–27.PubMedCrossRef

37.

Poon R, Fan S, Lo C, Liu C, et al. Hepatocellular carcinoma in the elderly: Results of surgical and nonsurgical management. The American Journal of Gastro-enterology, 1999; 94: 2460–2466.

38.

Shirabe K, Kajiyama K, Harimoto N, et al. Early outcome following hepatic resection in patients older than 80 years of age. World J Surg, 2009; 33: 1927–1932.PubMedCrossRef

39.

Hanazaki K, Kajikawa S, Shimozawa N, et al. Hepatic Resection for Hepatocellular Carcinoma in the Elderly. JAm Coll Surg, 2001; 192: 38–46.CrossRef

40.

Kazuto T, Yukihiro S. Practical guidelines for diagnosis and early management of druginduced liver injury. World J Gastroenterol 2008; 14: 6774–6785.CrossRef

41.

Verma S, Kaplowitz N. Diagnosis, management and prevention of drug-induced liver injury. Gut 2009; 58: 1555–1564.PubMedCrossRef

42.

NorrisW, Angelo H, Lewis J. Drug-induced liver injury in 2007. Curr Opin Gastroenterol 24: 287–297.

Titel: Leverlijden bij oudere personen
Auteurs: dr. T. Ghillemijn
W. Laleman
J. Flamaing
Publicatiedatum: 01-10-2011
Uitgeverij: Bohn Stafleu van Loghum
Gepubliceerd in: Tijdschrift voor Gerontologie en Geriatrie / Uitgave 5/2011
Print ISSN: 0167-9228
Elektronisch ISSN: 1875-6832
DOI: https://doi.org/10.1007/s12439-011-0038-x

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen

Andere artikelen Uitgave 5/2011

Congresagenda

Een handreiking voor familieleden over palliatieve zorg bij dementie: evaluatie door zorgverleners en familieleden

Signalementen

Recente onderzoeksliteratuur

Dementiediagnostiek bij oudere migranten op de geheugenpolikliniek: obstakels en oplossingen